In two successive cohorts of patients with Dravet syndrome (CRéER-1 1991–2004, CRéER-2 2005–2021) who initiated stiripentol before 2 years of age, the percentage of responders with a 50%, 75%, 100% (seizure free [SF]) decrease in both 5–30 minute- and >30 minute-duration tonic–clonic seizures (TCS) continued to increase between short-term and long-term treatment (light and dark columns respectively). Stiripentol also decreased the frequency of emergency hospitalizations.
This original article is commented on by Vasquez and Wirrell on pages 1545–1546 of this issue.
Please check your email for instructions on resetting your password.
If you do not receive an email within 10 minutes, your email address may not be registered,
and you may need to create a new Wiley Online Library account.
Request Username
Can't sign in? Forgot your username?
Enter your email address below and we will send you your username
If the address matches an existing account you will receive an email with instructions to retrieve your username